This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective was to assess the cost-effectiveness of long-term etanercept (ETN) treatment in patients with severe ankylosing spondylitis (AS).
Interventions
The interventions compared were ETN with non-steroidal anti-inflammatory drugs (NSAIDs), and NSAIDs alone.
Location/setting
UK/primary and secondary care.
Methods

Analytical approach:
A mathematical model was used to estimate the costs and benefits of the interventions. The time-horizon was 25 years and the authors stated the study perspective to be that of the National Health Service.
Effectiveness data:
The estimates of the initial response to treatment were obtained from a European randomised controlled trial (RCT), which compared ETN with placebo and 88% of patients in the placebo arm received NSAIDs. Data on the long-term disease progression was taken from published studies. The main clinical parameters were changes in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI).
Monetary benefit and utility valuations:
: The utility values were obtained by transforming, using a mathematical relationship, the BASDAI, BASFI, and European Quality of life (EQ-5D) data, collected during the European RCT.
Measure of benefit:
The primary measure of benefit was the quality-adjusted life-year (QALY) and these were discounted at an annual rate of 3.5%.
Cost data:
The costs associated with medications, hospitalisations and physiotherapy were included in the analysis. The resource use data were obtained from a cost study including 147 AS patients attending a rheumatology centre in England. The cost estimates were taken from various datasets. All costs were reported in UK pounds sterling (£) and were discounted at an annual rate of 3.5%.
